^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

sunvozertinib (DZD9008)

i
Other names: DZD9008, DZD-9008, DZD 9008
Company:
Dizal Pharma
Drug class:
EGFR inhibitor, HER2 inhibitor, BTK inhibitor
Related drugs:
3d
Enrollment open • Metastases
|
sunvozertinib (DZD9008)
26d
DZD9008 PK Study in Hepatic Impairment Subjects (clinicaltrials.gov)
P1, N=20, Recruiting, Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Trial completion date • Trial primary completion date
|
sunvozertinib (DZD9008)
1m
New P2 trial • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Avastin (bevacizumab) • sunvozertinib (DZD9008)
2ms
The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors. (PubMed, JTO Clin Res Rep)
EGFR-C797S in cis to all EGFR mutations evaluated generated dependent cells that were resistant to the covalent EGFR tyrosine kinase inhibitors mobocertinib, zipalertinib, furmonertinib, sunvozertinib, poziotinib, and osimertinib. This report highlights that poziotinib and mobocertinib are susceptible to on-target resistance mediated by EGFR-T790M or -C797S in the background of the most prevalent EGFR exon 20 insertion mutations. Furmonertinib, sunvozertinib, and to a less extent zipalertinib can overcome EGFR-T790M compound mutants, whereas EGFR-C797S leads to covalent inhibitor cross-resistance-robust data that support the limitations of mobocertinib and should further spawn the development of next-generation covalent and reversible EGFR exon 20 insertion mutation active inhibitors with favorable therapeutic windows that are less vulnerable to on-target resistance.
Journal • EGFR exon 20
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR T790M • EGFR exon 20 insertion • EGFR wild-type • EGFR C797S • EGFR exon 20 mutation • EGFR D770_N771insSVD • EGFR A767_V769dup • EGFR A767_V769dupASV
|
Tagrisso (osimertinib) • Pozenveo (poziotinib) • Ivesa (furmonertinib) • Exkivity (mobocertinib) • sunvozertinib (DZD9008) • zipalertinib (CLN-081)
3ms
New P1/2 trial • Metastases
|
sunvozertinib (DZD9008)
3ms
New P2 trial • Metastases
|
Focus V (anlotinib) • sunvozertinib (DZD9008)
3ms
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial. (PubMed, Lancet Respir Med)
In this phase 2 study, sunvozertinib demonstrated antitumour efficacy in patients with platinum-based chemotherapy pretreated NSCLC with EGFR exon20ins, with a manageable safety profile. A multinational randomised, phase 3 study of sunvozertinib versus platinum-doublet chemotherapy in EGFR exon20ins NSCLC is ongoing (NCT05668988).
P2 data • Journal • IO biomarker • EGFR exon 20 • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
|
sunvozertinib (DZD9008)
4ms
Sunvozertinib: First Approval. (PubMed, Drugs)
Clinical studies of sunvozertinib are underway in several countries worldwide. This article summarizes the milestones in the development of sunvozertinib leading to this first approval for metastatic NSCLC with EGFR exon20ins.
Review • Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 20 insertion • EGFR wild-type • EGFR exon 20 mutation
|
sunvozertinib (DZD9008)
5ms
DZD9008 PK Study in Hepatic Impairment Subjects (clinicaltrials.gov)
P1, N=20, Recruiting, Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
sunvozertinib (DZD9008)
5ms
China clinical practice guideline for epidermal growth factor receptor tyrosine kinase inhibitors in stage Ⅳ non-small cell lung cancer (version 2023) (PubMed, Zhonghua Yi Xue Za Zhi)
As of August 23, 2023, the first generation EGFR-TKIs, gefitinib, icotinib, and erlotinib; the second generation EGFR-TKIs, afatinib and dacomitinib; and the third generation EGFR-TKIs, osimertinib, almonertinib, furmonertinib and befotertinib were all approved for marketing by China National Medical Products Administration (NMPA). In addition, multiple domestic third-generation EGFR-TKIs are undergoing clinical trials, such as rezivertinib (BPI-7711), limertinib (ASK120067), and oritinib (SH-1028). Meanwhile, mobocertinib and sunvozertinib, which targets EGFR 20ins mutations, were also approved by NMPA. With the increasing variety of EGFR-TKIs approved for marketing subsequently, it brings confusion to clinicians when choosing specific medications, and there is an urgent need to develop relevant treatment guidelines. Hence, the Medical Oncology Branch of China International Exchange and Promotive Association for Medical and Health Care and the Chinese Association for Clinical Oncologists convened experts to integrate the research results of various EGFR-TKIs, and proposed the "China clinical practice guideline for epidermal growth factor receptor tyrosine kinase inhibitors in stage Ⅳ non-small cell lung cancer (version 2023)", to provide reference for better clinical practice.
Clinical guideline • Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Tagrisso (osimertinib) • erlotinib • Gilotrif (afatinib) • gefitinib • Conmana (icotinib) • Ameile (aumolertinib) • Vizimpro (dacomitinib) • Ivesa (furmonertinib) • Exkivity (mobocertinib) • Semena (befotertinib) • sunvozertinib (DZD9008) • rezivertinib (BPI-7711) • limertinib (ASK120067) • oritinib (SH-1028)
5ms
DZD9008 PK Study in Hepatic Impairment Subjects (clinicaltrials.gov)
P1, N=20, Not yet recruiting, Dizal (Jiangsu) Pharmaceutical Co., Ltd.
New P1 trial
|
sunvozertinib (DZD9008)
7ms
Secondary mutations of the EGFR gene that confer resistance to mobocertinib in EGFR exon 20 insertion. (PubMed, J Thorac Oncol)
T790M or C797S, depending on the original X20ins mutations, conferred acquired resistance to mobocertinib. Sunvozertinib may be the treatment of choice for patients with tumors resistant to mobocertinib because of T790M.
Journal • EGFR exon 20
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR T790M • EGFR exon 20 insertion • EGFR C797S • EGFR exon 20 mutation
|
erlotinib • Exkivity (mobocertinib) • sunvozertinib (DZD9008) • zipalertinib (CLN-081)
8ms
EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates. (PubMed, Transl Lung Cancer Res)
The majority of EGFR exon 20 insertions occur within the loop following the regulatory C-helix and activate the kinase domain of EGFR without generating a therapeutic window to gefitinib, erlotinib, afatinib, dacomitinib or osimertinib...The clinical development of kinase inhibitors for ERBB2-mutated NSCLC has been thwarted by mucocutaneous/gastrointestinal toxicities that preclude a pathway for drug approval, as the case of poziotinib...Other therapies in clinical development include sunvozertinib and zipalertinib, among others. In addition, traditional cytotoxic chemotherapy has some activity in these tumors. The approvals of mobocertinib, amivantamab, and trastuzumab deruxtecan represent the first examples of precision oncology for EGFR exon 20 insertion-mutated and ERBB2-mutated NSCLCs.
Review • Journal • EGFR exon 20
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
|
EGFR mutation • HER-2 mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
|
Tagrisso (osimertinib) • erlotinib • Gilotrif (afatinib) • gefitinib • Enhertu (fam-trastuzumab deruxtecan-nxki) • Vizimpro (dacomitinib) • Rybrevant (amivantamab-vmjw) • Pozenveo (poziotinib) • Exkivity (mobocertinib) • sunvozertinib (DZD9008) • zipalertinib (CLN-081)
8ms
Sunvozertinib as first-line treatment in NSCLC patients with EGFR Exon20 insertion mutations (ESMO 2023)
Conclusions In the 1st line setting, sunvozertinib as monotherapy demonstrated promising anti-tumor efficacy and acceptable safety profile in NSCLC patients with EGFR exon20ins. A phase III, multinational, randomized study (WU-KONG28, NCT05668988) is ongoing to compare sunvozertinib to chemotherapy as 1st line treatment for EGFR exon20ins NSCLC.
Clinical • EGFR exon 20
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 20 insertion • EGFR wild-type • EGFR exon 20 mutation
|
sunvozertinib (DZD9008)
8ms
On-Target Acquired Resistance to Mobocertinib and Strategy to Overcome It - In Vitro Study Using EGFR Ex20 Insertion Models (IASLC-WCLC 2023)
However, a novel EGFR-TKI, mobocertinib, was approved by the US FDA for NSCLC patients with EGFR exon20 insertion. We examined efficacy of mobocertinib and other EGFR-TKIs (erlotinib, afatinib, poziotinib, CLN-081, sunvozertinib , osimertinib, and brigatinib) using murine pro-B-cell line (Ba/F3) models harboring one of five most common EGFR exon 20 insertions (A763_Y764insFQEA, V769_D770insASV, D770_N771insSVD, H773_V774insNPH and H773_V774insH). These findings indicate that T790M or C797S, depending on the original activating mutations, will cause acquired resistance to mobocertinib in NSCLCs with EGFR exon 20 mutations. Further analyses suggest that sunvozertinib will be effective against acquired resistant cells with T790M mutation. However, except for A763_Y764insFQEA plus C797S mutation that is sensitive to erlotinib, other treatment strategy, such as cytotoxic chemotherapy, should be considered for patients who develop C797S secondary mutation.
Preclinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR T790M • EGFR exon 20 insertion • EGFR C797S • EGFR A763_Y764insFQEA • EGFR exon 20 mutation
|
Tagrisso (osimertinib) • erlotinib • Gilotrif (afatinib) • Alunbrig (brigatinib) • Pozenveo (poziotinib) • Exkivity (mobocertinib) • sunvozertinib (DZD9008) • zipalertinib (CLN-081)
8ms
Tumor Tissue and Plasma EGFR Exon 20 Insertion Mutation Status in NSCLC Patients Treated with Sunvozertinib (IASLC-WCLC 2023)
The EGFRexon20ins concordance between tumor tissue-based and plasma ctDNA testing is high. Antitumor activity of sunvozertinib was robust regardless of tumor tissue-based or plasma ctDNA tests. Both tests can be applied for identifying patients who potentially benefit from sunvozertinib treatment.
Clinical • EGFR exon 20
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 20 insertion • EGFR wild-type • KIT mutation • EGFR exon 20 mutation
|
OncoCompass™ Target • OncoScreen™ Focus CDx Tissue Kit
|
sunvozertinib (DZD9008)
9ms
New P1 trial • Metastases
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
|
EGFR mutation • HER-2 mutation
|
sunvozertinib (DZD9008)
9ms
Enrollment open • EGFR exon 20 • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
|
carboplatin • pemetrexed • sunvozertinib (DZD9008)
11ms
Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results. (ASCO 2023)
The first pivotal study results confirmed sunvozertinib’s superior anti-tumor efficacy than the current available therapy for NSCLC with EGFR exon20ins. The safety profile from WU-KONG6 study was consistent with previously reported findings. The updated data will be presented at the meeting.
IO biomarker • EGFR exon 20
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 20 insertion • EGFR wild-type • EGFR exon 20 mutation
|
sunvozertinib (DZD9008)
11ms
Efficacy and safety of sunvozertinib in treatment naïve NSCLC patients with EGFR exon20 insertion mutations. (ASCO 2023)
Consistent with second line results, sunvozertinib demonstrated promising efficacy and safety profile as monotherapy in the first line setting for patients with advanced EGFR exon20ins NSCLC. The updated data will be presented at the conference. A phase III, multinational, randomized study (WU-KONG28, NCT05668988) is ongoing to compare sunvozertinib to chemotherapy as first line treatment for EGFR exon20ins NSCLC.
Clinical • EGFR exon 20
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 20 insertion • EGFR wild-type • EGFR exon 20 mutation
|
sunvozertinib (DZD9008)
1year
TY-4028: a novel, targeted therapy for non small-cell lung cancer with EGFR exon 20 or HER2 exon 20 insertion mutations (AACR 2023)
In addition, trastuzumab and EGFR-TKIs have limited effectiveness for NSCLC patients with HER2 exon 20ins mutation. TAK-788 (mobocertinib) and JNJ6372 (amivantamab-vmjw) are the FDA approvals for NSCLC driven by EGFR exon 20ins mutations. Only T-Dxd is used as a second-line treatment for NSCLC patients with HER2 mutation...In EGFR-related tumor cells and genetically engineered Ba/F3 cell lines, TY-4028 showed similar or better antitumor effects than TAK-788, and better antitumor effects than DZD9008...#Jun Li and Chengshan Niu contributed equally to this work. *They are the correspondent authors.
EGFR exon 20 • HER2 exon 20
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
|
EGFR mutation • HER-2 mutation • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR exon 20 mutation • HER-2 exon 23 mutation
|
Herceptin (trastuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Rybrevant (amivantamab-vmjw) • Exkivity (mobocertinib) • sunvozertinib (DZD9008) • TY-4028
1year
New P2 trial • EGFR exon 20 • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
|
sunvozertinib (DZD9008)
1year
WK-KONG1: Assessing an Oral EGFR Inhibitor, DZD9008 in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) (clinicaltrials.gov)
P1/2, N=336, Recruiting, Dizal Pharmaceuticals | Trial completion date: Mar 2023 --> Jul 2024 | Trial primary completion date: Dec 2022 --> Oct 2023
Trial completion date • Trial primary completion date • HER2 exon 20 • Metastases
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
|
EGFR mutation • HER-2 mutation • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR exon 20 mutation • HER-2 exon 23 mutation
|
sunvozertinib (DZD9008)
1year
New P3 trial • EGFR exon 20 • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
|
carboplatin • pemetrexed • sunvozertinib (DZD9008)
over1year
New trial • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
|
sunvozertinib (DZD9008)
over1year
Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations (IASLC-NACLC 2022)
The data suggest sunvozertinib is active in both treatment naïve and prior platinum-based chemo treated NSCLC patients with EGFR Exon20ins. as well as in patients with CNS metastasis. Two pivotal studies (NCT03974022 and China CTR20211009) are ongoing and the updated data will be presented at the meeting.
Clinical • EGFR exon 20
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
|
sunvozertinib (DZD9008)
over1year
Identification of STX-721, an EGFR exon 20 mutant inhibitor with superior selectivity and a potential best-in-class profile (AACR-NCI-EORTC 2022)
STX-721 demonstrates EGFR exon 20 mutant selectivity approaching the selectivity of Osimertinib in EGFR T790M mutants, warranting further exploration of this potential best-in-class exon 20 inhibitor in the clinic. Ba/F3: proliferation selectivity vs. EGFR WT Human cells: proliferation selectivity (vs.
EGFR exon 20
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR wild-type • EGFR exon 20 mutation • EGFR H1975
|
Tagrisso (osimertinib) • Pozenveo (poziotinib) • Exkivity (mobocertinib) • tuxobertinib (BDTX-189) • sunvozertinib (DZD9008) • zipalertinib (CLN-081) • STX-721
over1year
Non-small cell lung cancer with EGFR exon 20 insertion mutation: a systematic literature review and pooled analysis of patient outcomes. (PubMed, Curr Med Res Opin)
Interventional studies reported outcomes for TKIs (mobocertinib, poziotinib, osimertinib, afatinib, CLN-081, DZD9008), a monoclonal antibody (amivantamab), and a heat shock protein 90 inhibitor (luminespib). Conventional treatments used in patients with EGFR exon 20 insertion mutation-positive NSCLC have limited efficacy, though chemotherapy appeared to be associated with better response and survival outcomes than non-exon 20 targeting EGFR-TKIs and IO agents. This supports the need to identify EGFR exon 20 insertion mutations as the availability of new targeted treatments may offer additional therapeutic options to these patients.
Retrospective data • Review • Journal • IO biomarker • EGFR exon 20
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
|
Tagrisso (osimertinib) • Gilotrif (afatinib) • Rybrevant (amivantamab-vmjw) • Pozenveo (poziotinib) • Exkivity (mobocertinib) • luminespib (AUY922) • sunvozertinib (DZD9008) • zipalertinib (CLN-081)
over1year
Sunvozertinib for NSCLC patients with EGFR exon 20 insertion mutations: Preliminary analysis of WU-KONG6, the first pivotal study (ESMO 2022)
The safety profile from WU-KONG6 study was consistent with previously reported findings. A global multi-center pivotal study (NCT03974022) with the same study design is ongoing in Asia, Europe, Australia and US.
Clinical • EGFR exon 20
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 20 insertion • EGFR wild-type • EGFR exon 20 mutation
|
sunvozertinib (DZD9008)
almost2years
Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations: Effect of Prior Treatment (IASLC-WCLC 2022)
The data suggest sunvozertinib is active in NSCLC patients with EGFR Exon20ins, irrespective of categories of prior treatment. The updated data will be presented at the meeting. Sunvozertinib is currently in phase 2 pivotal clinical development (NCT03974022 and China CTR20211009).
Clinical • EGFR exon 20
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
|
sunvozertinib (DZD9008)
almost2years
Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD(L)1 treatment failures. (ASCO 2022)
The data suggest sunvozertinib is active in platinum-pretreated patients with EGFR Exon20ins, irrespective of prior or after anti-PD(L)1 treatment. The updated data will be presented at the meeting. Sunvozertinib is currently in phase 2 pivotal clinical development (NCT03974022 and China CTR20211009).
Clinical • EGFR exon 20
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
|
sunvozertinib (DZD9008)
almost2years
Sunvozertinib, a selective EGFR inhibitor for previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations. (PubMed, Cancer Discov)
Epidermal growth factor receptor exon 20 insertion mutations (EGFR exon20ins) are detected in approximately 2% of patients with non-small cell lung cancer (NSCLC). Antitumor efficacy was observed at the doses of 100 mg and above in patients with EGFR exon20ins NSCLC across different subtypes, with prior amivantamab treatment as well as with baseline brain metastasis. The median duration of response (DoR) has not been reached.
Journal • EGFR exon 20
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
|
Rybrevant (amivantamab-vmjw) • sunvozertinib (DZD9008)
2years
Enrollment change
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
|
EGFR mutation • HER-2 mutation • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR exon 20 mutation • HER-2 exon 23 mutation
|
sunvozertinib (DZD9008)
over2years
[VIRTUAL] Phase 1 Studies of DZD9008, an Oral Selective EGFR/HER2 Inhibitor in Advanced NSCLC with EGFR Exon20 Insertion Mutations (IASLC-WCLC 2021)
These patients received median 2 (range 1 - 10) lines of prior therapies, including prior chemotherapy 92.9% (52/56), prior EGFR TKI 44.6% (25/56) (1 patient had poziotinib treatment), onco-immunotherapy 30.4% (17/56), VEGFR antibody 41.1% (23/56), JNJ-61186372 7.1% (4/56) and others 17.9% (10/56). Conclusion DZD9008 showed a favourable safety profile and promising anti-tumor efficacy in pre-treated NSCLC with EGFR exon20ins and other EGFR or HER2 mutations. DZD9008 is currently in phase 2 clinical development in EGFR Exon20ins NSCLC.
P1 data • IO biomarker • EGFR exon 20
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • HER-2 mutation • EGFR T790M • EGFR exon 20 insertion • EGFR exon 20 mutation
|
Rybrevant (amivantamab-vmjw) • Pozenveo (poziotinib) • sunvozertinib (DZD9008)
almost3years
[VIRTUAL] Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations. (ASCO 2021)
Prior therapies: median 2 (range 1 - 10), prior chemotherapy 92.9% (52/); prior TKI 44.6% (25/56) including 1 patient had poziotinib treatment; 42.9% (24/56) with brain metastasis...Responses were observed in 2 patients with prior JNJ-61186372 treatment... DZD9008 showed a favorable safety profile and promising anti-tumor efficacy in pre-treated NSCLC with EGFR exon20ins mutations . The updated data will be presented at the meeting . DZD9008 is currently in phase II clinical development (NCT03974022).
Clinical • P1 data • EGFR exon 20
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
|
EGFR mutation • HER-2 mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
|
Rybrevant (amivantamab-vmjw) • Pozenveo (poziotinib) • sunvozertinib (DZD9008)
almost3years
Clinical • Enrollment change
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
|
EGFR mutation • HER-2 mutation • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR exon 20 mutation
|
sunvozertinib (DZD9008)